Form 4: SR One Capital Management IPO Conversion and Equity Update

SR One Capital Management reports the conversion of preferred stock and warrant exercises in connection with the Odyssey Therapeutics IPO.

Summary

• SR One Capital Management, LLC and associated entities converted multiple series of preferred stock (Series A, A-2, B, C, and D) into common stock of Odyssey Therapeutics, Inc. (ODTX).
• The conversions occurred immediately prior to the closing of the issuer's initial public offering.
• Series D warrants were exercised on a net exercise basis, resulting in the issuance of common shares after withholding shares for the exercise price.
• The reporting entities also engaged in open market purchases of common stock at $18.00 per share.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral, routine disclosure of ownership changes following an IPO, indicating stability in the major shareholder's position.

Positives

• Successful conversion of all held preferred stock series into common equity, simplifying the capital structure.
• Active participation in the company's equity through additional open market purchases at $18.00 per share.
• Demonstrates continued long-term commitment from a major 10% owner.

Negatives

• Minor dilution impact from the issuance of new common shares upon conversion and warrant exercise.
• Small amounts of shares were withheld by the issuer to cover exercise costs for the warrants.

Risks

• Market volatility associated with newly public companies.
• Concentration of ownership by SR One Capital Management may influence future corporate governance decisions.

Future Outlook

The filing does not provide forward-looking guidance on company operations, focusing instead on the reporting of ownership changes following the IPO.

Management Comments

• The reporting persons disclaim beneficial ownership of the shares except to the extent of any pecuniary interest therein.

Industry Context

StockSavvy.ai notes that this filing is a standard administrative requirement for institutional investors following an IPO, reflecting the transition of private venture capital holdings into public equity.

Comparison to Industry Standards

• The conversion ratios (ranging from 1-for-9.28 to 1-for-9.71) are consistent with standard venture-backed biotech IPO recapitalizations.
• Net exercise of warrants is a common practice to minimize cash outlay for institutional holders during liquidity events.

Stakeholder Impact

• Shareholders: Increased transparency regarding the conversion of preferred shares into common stock.
• Creditors: No direct impact disclosed.

Next Steps

• Continued monitoring of SR One Capital Management's holdings via future Form 4 filings.

Key Dates

Keywords

Odyssey Therapeutics, ODTX, SR One Capital Management, IPO, Convertible Preferred Stock, SEC Form 4, Insider Trading